Cargando…

Effects of the Antidiabetic Drugs Evogliptin and Sitagliptin on the Immune Function of CD26/DPP4 in Th1 Cells

This study aimed to investigate whether the antidiabetic drugs dipeptidyl peptidase 4 (DPP4) inhibitors such as evogliptin and sitagliptin affect the membrane DPP4 (mDPP4) enzymatic activity and immune function of T helper1 (Th1) cells in terms of cytokine expression and cell profiles. The mDPP4 enz...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yoon, Hyunyee, Sung, Ji Hyun, Song, Moon Jung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Society of Applied Pharmacology 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7921863/ https://www.ncbi.nlm.nih.gov/pubmed/33148870 http://dx.doi.org/10.4062/biomolther.2020.150

Ejemplares similares

Evogliptin, a DPP-4 inhibitor, prevents diabetic cardiomyopathy by alleviating cardiac lipotoxicity in db/db mice
por: Pham, Trong Kha, et al.
Publicado: (2023)

Efficacy and safety of adding evogliptin versus sitagliptin for metformin‐treated patients with type 2 diabetes: A 24‐week randomized, controlled trial with open label extension
por: Hong, Sang‐Mo, et al.
Publicado: (2017)

Protective Effects of Evogliptin on Steatohepatitis in High-Fat-Fed Mice
por: Kim, Jin Hyun, et al.
Publicado: (2020)

Dipeptidyl peptidase-4 (DPP-4; CD26)
Publicado: (2013)

CD26/DPP-4 in Chronic Myeloid Leukemia
por: Sicuranza, Anna, et al.
Publicado: (2022)

In Vitro Metabolic Pathways of the New Anti-Diabetic Drug Evogliptin in Human Liver Preparations
por: Jeong, Hyeon-Uk, et al.
Publicado: (2015)

Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
por: Ahrén, Bo
Publicado: (2010)

Effect of Rifampicin on the Pharmacokinetics of Evogliptin in Healthy Volunteers
por: Shin, Yesong, et al.
Publicado: (2022)

The Effect of Evogliptin Tartrate on Controlling Inflammatory Pain
por: Cho, Pyung Goo, et al.
Publicado: (2023)

Pharmacokinetic and pharmacodynamic interactions between metformin and a novel dipeptidyl peptidase-4 inhibitor, evogliptin, in healthy subjects
por: Rhee, Su-jin, et al.
Publicado: (2016)

Pharmacokinetic and pharmacodynamic drug–drug interactions between evogliptin and empagliflozin or dapagliflozin in healthy male volunteers
por: Kim, Dasohm, et al.
Publicado: (2023)

Saxagliptin but Not Sitagliptin Inhibits CaMKII and PKC via DPP9 Inhibition in Cardiomyocytes
por: Koyani, Chintan N., et al.
Publicado: (2018)

CD26/DPP-4: Type 2 Diabetes Drug Target with Potential Influence on Cancer Biology
por: Kawakita, Emi, et al.
Publicado: (2021)

The Serine Protease CD26/DPP4 in Non-Transformed and Malignant T Cells
por: Chitadze, Guranda, et al.
Publicado: (2021)

Functional roles of CD26/DPP4 in bleomycin‐induced pulmonary fibrosis
por: Koyanagi, Yu, et al.
Publicado: (2023)

Evogliptin Suppresses Calcific Aortic Valve Disease by Attenuating Inflammation, Fibrosis, and Calcification
por: Choi, Bongkun, et al.
Publicado: (2021)

Functional Dissection of CD26 and Its Pharmacological Inhibition by Sitagliptin During Skin Wound Healing
por: Jiang, Yue, et al.
Publicado: (2021)

CD26-Related Serum Biomarkers: sCD26 Protein, DPP4 Activity, and Anti-CD26 Isotype Levels in a Colorectal Cancer-Screening Context
por: De Chiara, Loretta, et al.
Publicado: (2020)

Sitagliptin, a DPP-4 Inhibitor, Acutely Inhibits Intestinal Lipoprotein Particle Secretion in Healthy Humans
por: Xiao, Changting, et al.
Publicado: (2014)

Pharmacokinetic/Pharmacodynamic Interaction Between Evogliptin and Pioglitazone in Healthy Male Subjects
por: Hwang, Inyoung, et al.
Publicado: (2020)

Pharmacokinetic/Pharmacodynamic Interactions Between Evogliptin and Glimepiride in Healthy Male Subjects
por: Yoo, Hyounggyoon, et al.
Publicado: (2020)

Evogliptin Directly Inhibits Inflammatory and Fibrotic Signaling in Isolated Liver Cells
por: Seo, Hye-Young, et al.
Publicado: (2022)

Insight into Structure Activity Relationship of DPP-4 Inhibitors for Development of Antidiabetic Agents
por: Mathur, Vishal, et al.
Publicado: (2023)

Evaluation of pleural effusion sCD26 and DPP-IV as diagnostic biomarkers in lung disease
por: Sánchez-Otero, Nuria, et al.
Publicado: (2014)

CD26/DPP4 as a Therapeutic Target in Nonalcoholic Steatohepatitis Associated Hepatocellular Carcinoma
por: Nishina, Sohji, et al.
Publicado: (2022)

Lung development and immune status under chronic LPS exposure in rat pups with and without CD26/DPP4 deficiency
por: Schmiedl, Andreas, et al.
Publicado: (2021)

Efficacy of evogliptin and cenicriviroc against nonalcoholic steatohepatitis in mice: a comparative study
por: Wang, Zheng, et al.
Publicado: (2019)

Antidiabetic Drug Sitagliptin with Divalent Transition Metals Manganese and Cobalt: Synthesis, Structure, Characterization Antibacterial and Antioxidative Effects in Liver Tissues
por: El-Megharbel, Samy M., et al.
Publicado: (2022)

Functional Roles for CD26/DPP4 in Mediating Inflammatory Responses of Pulmonary Vascular Endothelial Cells
por: Takahashi, Yukiko, et al.
Publicado: (2021)

Serum soluble CD26/DPP4 titer variation is a potential prognostic biomarker in cancer therapy with a humanized anti-CD26 antibody
por: Kaneko, Yutaro, et al.
Publicado: (2021)

Fixed drug eruption to sitagliptin
por: Gupta, Mrinal, et al.
Publicado: (2015)

Efficacy and safety of evogliptin monotherapy in patients with type 2 diabetes and moderately elevated glycated haemoglobin levels after diet and exercise
por: Park, Juri, et al.
Publicado: (2017)

DPP4 Inhibitor Sitagliptin Enhances Lymphocyte Recruitment and Prolongs Survival in a Syngeneic Ovarian Cancer Mouse Model
por: Wilson, Amy L., et al.
Publicado: (2021)

Identification of DPP4/CTNNB1/MET as a Theranostic Signature of Thyroid Cancer and Evaluation of the Therapeutic Potential of Sitagliptin
por: Cheng, Sheng-Yao, et al.
Publicado: (2022)

The Effect of Compression Pressure on the First Layer Surface Roughness and Delamination of Metformin and Evogliptin Bilayer and Trilayer Tablets
por: Kim, Sun Ho, et al.
Publicado: (2023)

Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers
por: Gu, Namyi, et al.
Publicado: (2014)

Beneficial Effects of Evogliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, on Adiposity with Increased Ppargc1a in White Adipose Tissue in Obese Mice
por: Chae, Yu-Na, et al.
Publicado: (2015)

Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled Type 2 diabetes on oral antidiabetic drugs in Greece
por: Tzanetakos, Charalampos, et al.
Publicado: (2014)

Comparative Binding Analysis of Dipeptidyl Peptidase IV (DPP-4) with Antidiabetic Drugs – An Ab Initio Fragment Molecular Orbital Study
por: Arulmozhiraja, Sundaram, et al.
Publicado: (2016)

Evogliptin, a Dipeptidyl Peptidase-4 Inhibitor, Attenuates Renal Fibrosis Caused by Unilateral Ureteral Obstruction in Mice
por: Kim, Mi-Jin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_t756668mb4q3d8n0omkfjlfp4m